Vandria's oral compound VNA-318 demonstrated safety and brain penetration in a 92-subject Phase 1 trial, with quantitative EEG changes and biomarkers consistent with mitochondrial restoration. The compound's pharmacokinetics support once-daily dosing and warrant progression to Alzheimer's disease trials.
Key Points
- Oral VNA-318 crossed blood-brain barrier; confirmed in cerebrospinal fluid
- 12-day dosing altered brain activity patterns measured by quantitative EEG
- Metabolite signatures aligned with energy restoration in preclinical models
Longevity Analysis
The ability to modulate brain bioenergetics through an orally bioavailable small molecule addresses a foundational driver of neurodegeneration. Mitochondrial dysfunction underpins cognitive decline across multiple pathways; restoring energy production capacity in neural tissue before irreversible loss occurs represents a mechanistic approach distinct from amyloid-centric strategies. The confirmation of pharmacodynamic activity in human CNS tissue, paired with favorable tolerability, shifts VNA-318 from theoretical benefit to measurable neurobiological effect—a necessary step before clinical efficacy can be evaluated in populations where this mitochondrial restoration may slow or stabilize decline.
Original published by Longevity.Technology.